Copyright
©The Author(s) 2021.
World J Gastroenterol. Mar 21, 2021; 27(11): 1090-1100
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1090
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1090
Figure 2 Total tolerability scores when comparing inflammatory bowel disease and non-inflammatory bowel disease cohorts.
Of 95 inflammatory bowel disease and 193 non- inflammatory bowel disease participants included. Higher score indicates better tolerability where 0 = poorly tolerated and 5 = well tolerated. Total score is out of 20 (0-5 for taste; 0-5 ease of ingestion; 0-5 for palatability; 0-5 for amount). IBD: Inflammatory bowel disease.
- Citation: Mohsen W, Williams AJ, Wark G, Sechi A, Koo JH, Xuan W, Bassan M, Ng W, Connor S. Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy? World J Gastroenterol 2021; 27(11): 1090-1100
- URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1090.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1090